Palvella Therapeutics, Inc. (FRA:PI6)

Palvella Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Selling, General & Admin	13.4	5.94	3.08	4.16
Research & Development	18.26	8.15	8.79	13.88
Operating Expenses	31.66	14.1	11.87	18.04
Operating Income	-31.66	-14.1	-11.87	-18.04
Interest Expense	-5.38	-4.32	-	-10.36
Interest & Investment Income	1.71	-	6.27	-
Other Non Operating Income (Expenses)	0.72	-0.12	1.2	-0.17
EBT Excluding Unusual Items	-34.62	-18.53	-4.41	-28.58
Other Unusual Items	1.67	1.1	23.1	-
Pretax Income	-32.95	-17.43	18.69	-28.58
Income Tax Expense	-	-	-	-1.03
Net Income	-32.95	-17.43	18.69	-27.55
Preferred Dividends & Other Adjustments	-0.58	-	14.81	-
Net Income to Common	-32.37	-17.43	3.88	-27.55
Shares Outstanding (Basic)	9	2	2	6
Shares Outstanding (Diluted)	9	2	2	6
Shares Change (YoY)	60.51%	24.08%	-68.63%	-
EPS (Basic)	-3.53	-7.83	2.19	-4.82
EPS (Diluted)	-3.53	-7.83	2.17	-4.82
EBIT	-31.66	-14.1	-11.87	-18.04

Source: S&P Global Market Intelligence. Standard template. Financial Sources.